title: Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib.
abstract: Mechanism-based inactivation (MBI) of CYP450 enzymes is a unique form of inhibition in which the enzymatic machinery of the victim is responsible for generation of the reactive metabolite. This precondition sets up a time-dependency for the inactivation process, a hallmark feature that characterizes all MBI. Yet, MBI itself is a complex biochemical phenomenon that operates in different modes, namely, covalent binding to apoprotein, covalent binding of the porphyrin group and also complexation of the catalytic iron. Using lapatinib as a recent example of toxicological interest, we present an example of a mixed-function MBI that can confound clinical drug-drug interactions manifestation. Lapatinib exhibits both covalent binding to the apoprotein and formation of a metabolite-intermediate complex in an enzyme-selective manner (CYP3A4 versus CYP3A5), each with different reactive metabolites. The clinical implication of this effect is also contingent upon genetic polymorphisms of the enzyme involved as well as the co-administration of other substrates, inhibitors or inducers, culminating in drug-drug interactions. This understanding recapitulates the importance of applying isoform-specific mechanistic investigations to develop customized strategies to manage such outcomes.
authors: Department of Pharmacy, Faculty of Science, National University of Singapore , Singapore and.
authors: Han Kiat
authors: HK
authors: Ho
authors: James Chun Yip
authors: JC
authors: Chan
authors: Klarissa D
authors: KD
authors: Hardy
authors: Eric Chun Yong
authors: EC
authors: Chan
mesh_terms: D000818:Animals; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism*; D006801:Humans; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000378:metabolism*; D011799:Quinazolines / Q000737:chemistry / Q000378:metabolism*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077341:Lapatinib; D051544:Cytochrome P-450 CYP3A
keywords: CYP3A; drug–drug interaction; lapatinib; mechanism-based inactivation; toxicity
references: Nat Genet. 2001 Apr;27(4):383-91
references: 11279519
references: Drug Metab Dispos. 2013 May;41(5):1012-22
references: 23404373
references: Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94
references: 12406645
references: Clin Exp Immunol. 1984 Mar;55(3):561-70
references: 6368059
references: Invest New Drugs. 2013 Jun;31(3):751-9
references: 23054212
references: Chem Commun (Camb). 2013 Oct 28;49(84):9779-81
references: 24026006
references: Drug Metab Dispos. 2014 Jan;42(1):162-71
references: 24191259
references: J Clin Oncol. 2013 Dec 20;31(36):4504-11
references: 24248687
references: Drug Metab Dispos. 2014 Mar;42(3):334-42
references: 24335391
references: J Am Chem Soc. 2002 Oct 9;124(40):11866-7
references: 12358527
references: Drug Metab Dispos. 2012 Aug;40(8):1460-5
references: 22613176
references: Curr Treat Options Oncol. 2012 Jun;13(2):230-9
references: 22410709
references: Breast Cancer Res Treat. 2012 Jun;133(2):703-11
references: 22370628
references: Drug Metab Dispos. 2012 May;40(5):998-1006
references: 22344702
references: Br J Clin Pharmacol. 2007 Nov;64(5):668-79
references: 17578481
references: Ann Oncol. 2007 Dec;18(12):2025-9
references: 17846021
references: J Clin Oncol. 2008 Jun 20;26(18):2999-3005
references: 18458039
references: Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61
references: 18762933
references: Br J Clin Pharmacol. 2009 Apr;67(4):421-6
references: 19371315
references: Drugs. 2009 Oct 22;69(15):2125-48
references: 19791830
references: Mol Pharmacol. 2010 Oct;78(4):693-703
references: 20624855
references: J Clin Oncol. 2011 Feb 20;29(6):667-73
references: 21245432
references: Drug Metab Dispos. 2011 Jun;39(6):1022-30
references: 21363997
references: Cancer Chemother Pharmacol. 2011 Dec;68(6):1529-36
references: 21519841
references: Drug Metab Dispos. 2012 Jan;40(1):139-50
references: 21965624
references: Br J Pharmacol. 2012 Apr;165(8):2787-98
references: 22014153
references: Drug Metab Dispos. 2012 Sep;40(9):1686-97
references: 22645092
references: Crit Rev Toxicol. 2007 Jun;37(5):389-412
references: 17612953
references: Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):51-66
references: 17269894
references: Drug Metab Dispos. 2007 Feb;35(2):246-55
references: 17093004
references: Annu Rev Pharmacol Toxicol. 2007;47:513-39
references: 16879083
references: Proc Natl Acad Sci U S A. 1987 Jan;84(2):551-5
references: 3540968
references: FASEB J. 1988 Sep;2(12):2774-83
references: 3044903
references: Biochemistry. 1994 Jan 11;33(1):166-75
references: 8286335
references: Annu Rev Pharmacol Toxicol. 1999;39:1-17
references: 10331074